百利天恒涨3.01% 基因药获批

智选洞察2025-04-29

04月29日，百利天恒（688506）股价大幅上涨，截至10点13分，百利天恒上涨3.01%，报293.59元/股，成交1.58亿元，换手率0.53%，振幅4.42%。消息解读4月上旬，我国首个基因替代疗法药物“信玖凝”获国家药品监督管理局批准上市，用于治疗中重度血友病B成年患者。该药由上海信致医药科技有限公司研发生产，采用重组腺相关病毒（rAAV）技术。此前，全球只有8款rAAV基因治疗药物获批...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531214239?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-29 10:13","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2531214239","market":"sh","top_or_hot":-1,"title":"百利天恒涨3.01% 基因药获批","media":"智选洞察","content":"<div>\n<p>04月29日，百利天恒（688506）股价大幅上涨，截至10点13分，百利天恒上涨3.01%，报293.59元/股，成交1.58亿元，换手率0.53%，振幅4.42%。消息解读4月上旬，我国首个基因替代疗法药物“信玖凝”获国家药品监督管理局批准上市，用于治疗中重度血友病B成年患者。该药由上海信致医药科技有限公司研发生产，采用重组腺相关病毒（rAAV）技术。此前，全球只有8款rAAV基因治疗药物获批...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910140797495a05&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒涨3.01% 基因药获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒涨3.01% 基因药获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-29 10:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910140797495a05&s=b><strong>智选洞察</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>04月29日，百利天恒（688506）股价大幅上涨，截至10点13分，百利天恒上涨3.01%，报293.59元/股，成交1.58亿元，换手率0.53%，振幅4.42%。消息解读4月上旬，我国首个基因替代疗法药物“信玖凝”获国家药品监督管理局批准上市，用于治疗中重度血友病B成年患者。该药由上海信致医药科技有限公司研发生产，采用重组腺相关病毒（rAAV）技术。此前，全球只有8款rAAV基因治疗药物获批...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910140797495a05&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910140797495a05&s=b","article_id":"2531214239","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910140797495a05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2531214239","pubTimestamp":1745892810,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"消息解读4月上旬，我国首个基因替代疗法药物“信玖凝”获国家药品监督管理局批准上市，用于治疗中重度血友病B成年患者。此前，全球只有8款rAAV基因治疗药物获批上市。主营业务及业绩百利天恒公司主营业务为药品的研发、生产及销售。最新财报显示，今年年报，百利天恒实现营业收入58.23亿元，同比增长936.31%，净利润为37.08亿元，同比增长575.02%，基本每股收益为9.25元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688506":"百利天恒","BK0239":"医药制造"},"translate_title":"Baili Tianheng rose 3.01%, genetic drugs were approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688506":1},"content_text":"04月29日，百利天恒（688506）股价大幅上涨，截至10点13分，百利天恒上涨3.01%，报293.59元/股，成交1.58亿元，换手率0.53%，振幅4.42%。消息解读4月上旬，我国首个基因替代疗法药物“信玖凝”获国家药品监督管理局批准上市，用于治疗中重度血友病B成年患者。该药由上海信致医药科技有限公司研发生产，采用重组腺相关病毒（rAAV）技术。此前，全球只有8款rAAV基因治疗药物获批上市。“信玖凝”的上市，拓展了国产创新药市场新版图。4月下旬，上海药企君实生物研发的特瑞普利单抗注射液获国家药品监督管理局批准，用于治疗黑色素瘤患者。作为以PD-1为靶点获批的国内首个单抗药物，特瑞普利此前已有11项获批适应证纳入《国家医保目录（2024年）》，目前是目录中唯一用于黑色素瘤、非小细胞肺癌围手术期、肾癌、三阴性乳腺癌治疗的抗PD-1药物。近期，一名淋巴瘤患者在香港顺利完成CAR-T细胞治疗药品注射。不同于传统药品，细胞治疗产品作为“从血管到血管”活的药物，需提取患者白细胞，通过冷链运输到细胞工厂，制备和检测CAR-T细胞后，经深冷运输回输到患者体内。这不仅是全国首例CAR-T细胞治疗药品跨境运输使用，耗时不到48小时，更是上海首创生物医药特殊物品进出境联合监管机制取得的重要成果。该细胞治疗药品由复星凯瑞（上海）生物科技有限公司生产。此外，数据统计显示，近半年内8家券商给予买入建议。资金动向截止发稿，百利天恒获得主力净流入425万元，其中超大单流入4万元，大单流入420万元。数据显示，该股今日净流入较近5日净流入均值减少205万元。主营业务及业绩百利天恒公司主营业务为药品的研发、生产及销售。最新财报显示，今年年报，百利天恒实现营业收入58.23亿元，同比增长936.31%，净利润为37.08亿元，同比增长575.02%，基本每股收益为9.25元。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531214239","isCrawlerRequest":true}